London-listed gene therapy company Oxford Biomedica has brought on pharmaceutical executive Colin Bond as a board member as Leone Patterson steps down. 

Bond, who will join the life sciences firm in January 2025, started his career as a pharmacist and management consultant at firms including Procter & Gamble, Arthur Andersen and PwC. 

More recently, Bond worked as chief financial officer at the Zürich-listed pharmaceutical company Sandoz. Bond has also held executive positions at Vifor Pharma and Evotec. 

“Oxford Biomedica’s position as a leader in cell and gene therapy manufacturing, combined with its innovative approach and strong client partnerships, presents a compelling opportunity that I have recently watched with interest,” said Bond. 

I am excited to join the board at this important time and look forward to working with the team to support Oxford Biomedica’s continued growth and success in enabling the delivery of life-changing therapies to patients worldwide.” 

The appointment of Bond comes as Leone Patterson announces her resignation as a non-executive from Oxford Biomedica to focus on her responsibilities as the newly appointed CFO and chief business officer at Zymeworks. 

“I would like to thank Leone for her sharp analytical insights and active contributions to Oxford Biomedica during her tenure on the Board and wish her the very best with her new responsibilities,” added Oxford Biomedica chair Roch Doliveux. 

Founded in 1995, the Oxford-based biotech specialises in the development and manufacturing of gene and cell therapies used to treat and prevent diseases. 

The company went public on the London Stock Exchange in 1996. In its accounts for the year ended December 2023, the firm reported an operating loss of £184.2m, more than five times more its £30.2m loss in 2022. 

Revenue for the period dropped by more than a third to £89.5m. As of 11:00 on 18 November, Oxford Biomedica shares were priced at 410.43p. 

Already have an account? Log in